Via practica 5/2018
Optimal treatment of venous thromboembolism
Venous thromboembolism involving deep vein thrombosis as well as pulmonary embolism represents a frequent and costly disease that is associated with high morbidity and mortality rates. The main goal of treatment is to prevent pulmonary embolism and death related to venous thrombosis and pulmonary embolism as well as to prevent chronic venous insufficiency and chronic thromboembolic pulmonary hypertension. In addition to treatment with low-molecular-weight heparin and warfarin, there has been a trend in the last five years to increasingly use direct oral anticoagulants in treatment; these include the so-called xabans (rivaroxaban, apixaban, edoxaban), direct inhibitors of activated factor Xa, and the so-called gatrans, including dabigatran that inhibits activated factor IIa. The case report presents modern methods of treating acute-stage venous thromboembolism and subsequent secondary long-term prophylaxis in a patient with recurrent venous thrombosis who, in the course of treatment, had to undergo acute surgery with the need to administer an antidote in order to rapidly eliminate the anticoagulant effect of dabigatran from the body.
Keywords: venous thromboembolism, treatment, DOAC (direct oral anticoagulants), dabigatran
